Φορτώνει......
Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. Since its introduction, the expertise of prescribing doctors with respect to ruxolitinib function, efficacy and adverse effe...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Wien Klin Wochenschr |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Vienna
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6132876/ https://ncbi.nlm.nih.gov/pubmed/30043249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00508-018-1365-5 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|